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Abstract: The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene de-
fect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within the first 
weeks or months of life is inevitable. Some diseases can be managed using conventional medicines whereas others are, as yet, untreat-
able. In this review we consider the application of early intervention gene therapy in neonatal and fetal preclinical studies. We appraise 
the tools of this technology, including lentivirus, adenovirus and adeno-associated virus (AAV)-based vectors. We highlight the applica-
tion of these for a range of diseases including hemophilia, urea cycle disorders such as ornithine transcarbamylase deficiency, organic 
acidemias, lysosomal storage diseases including mucopolysaccharidoses, glycogen storage diseases and bile metabolism. We conclude by 
assessing the advantages and disadvantages associated with fetal and neonatal liver gene transfer.  
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1. INTRODUCTION 
  The importance of the liver has been recognised for thousands 
of years. During the reign of the Egyptian empire the god Imsety 
was believed to protect the canopic jar that held the liver of the 
deceased. At this time, the Egyptians thought that the liver was the 
seat of emotion. Modern medicine has recognised the liver as being 
the seat of many fundamental functions including; amino acid me-
tabolism, transamination, plasma protein synthesis, storage of gly-
cogen, and bile production. During the 1990s gene therapy went 
from being vaunted as a panacea to being vilified as snake oil. 
However the first decade of this new millennium has witnessed a 
‘renaissance’ within the field as, case by case, clinical successes of 
gene therapy have been demonstrated.  
  In this review we first consider the main vector classes that 
have been used for liver gene transfer in fetal neonatal models, 
namely adenoviral vectors, retroviral vectors (specifically gamma 
retroviral and lentiviral vectors), adeno-associated viral vectors and 
non-viral vectors. We proceed to detail classes of disease which 
have been studied in preclinical models including coagulopathies, 
urea cycle disorders, organic acidemias, lysosomal storage diseases, 
glycogen storage diseases and disorders of bile metabolism. Finally 
we overview the advantages, disadvantages and questions facing 
the concept of fetal and neonatal gene therapy including risks of 
genotoxicity, the diseases which may benefit from early interven-
tion, and the choice of vector depending upon the disease. For a 
broader, rather than a liver-based, perspective on the concepts and 
technologies underlying fetal gene transfer the reader is directed to 
recent and extensive reviews on the subject matter [1-5]. 
2. VECTOR SYSTEMS FOR FETAL AND NEONATAL 
GENE TRANSFER 
2.1. Adenoviral Vectors 
  Adenovirus-based vectors have been used for gene delivery to a 
wide range of cells and organs and have been implemented in many 
preclinical studies. Adenoviral vectors contain a DNA payload that, 
when delivered, remains episomal within the nuclei of infected 
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cells. Fifty-one known human adenovirus serotypes are categorised 
into six subgroups, A-F. Most commonly, serotype 5 (Ad5) has 
been used for preclinical and clinical trials. However, enthusiasm 
for its use has been blunted by the high prevalence of pre-existing 
anti-Ad5 immunity in mice, rhesus monkeys and humans [6]. Elu-
cidating the complex interaction between receptors, capsid ele-
ments, blood cells and proteins is critical to its adoption in clinical 
settings. In 1993, Ad5 was shown to depend upon v3 and v5 
integrin for virus internalisation [7]. In 1997, the primary receptor 
for the Ad5 fiber was shown to be the coxsackie and adenovirus 
receptor (CAR) [8, 9]. However these receptors did not account for 
the high efficiency for Ad5 in binding to the liver. Recently we 
[10], and others [11, 12], have shown that coagulation factor X 
(FX) acts as a molecular bridge between the adenovirus hexon hy-
pervariable regions and cell surface ligands. This interaction is the 
major mediator for in vivo infection of hepatocytes in rats and mice. 
By administering warfarin [13] to deplete all vitamin K-dependent 
coagulation factors or by injection of specific pharmacological 
inhibitors of FX, such as factor X-binding protein, adenovirus in-
fection can be profoundly inhibited in the liver and substantially 
reduced in other organs including the lung, heart and spleen [10, 
14]. Liver infection can also be inhibited by genetic modification of 
Ad5 hypervariable regions 5 and 7 [15].  
  For anti-cancer studies, adenoviral vectors that are capable of 
replication in selective environments have been developed [16, 17]. 
However, for a high proportion of preclinical and clinical studies, 
first and second generation adenoviral vectors have been employed 
where viral genes including E1 and E3 have been deleted. These 
vectors are incapable of independent replication but still express 
other viral genes at a low level that contributes to toxicity and tran-
sient expression, which are often seen following application of 
these vectors. To reduce this toxicity and increase the vector pay-
load further, fully-deleted “gutless” vectors have been developed. 
These are known as helper-dependent adenoviral vectors, contain 
no viral genes and therefore encode no viral proteins. These vector 
iterations are reviewed by Alba and colleagues [18]. 
2.2. Retroviral Vectors 
  Retrovirus virions contain two RNA strands of genome that are 
associated with a reverse transcriptase molecule within a protein 
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initiates reverse transcription of the RNA genome to DNA that 
integrates into the host cell genome facilitated by the virally tran-
scribed integrase. The lipid bilayer coat, budded from the host cell 
membrane, displays virally transcribed receptors that determine 
tropism. Gene delivery vectors have been developed based upon 
several genera of the Retroviridae family including Avian leukosis 
sarcoma virus (genus Alpharetrovirus) [19], human foamy virus 
(genus Spumavirus) [20] but most commonly Moloney murine 
leukemia virus (MLV) (genus Gammaretrovirus) and Human Im-
munodeficiency Virus type (HIV)-1 (genus Lentivirus) [21]. The 
application of retroviridae as gene transfer vectors was limited in 
the early stages by their physical instability, resulting in reductions 
of active half-life and an inability to substantially increase viral titre 
by standard methodologies, such as caesium chloride centrifugation 
or ultracentrifugation. Furthermore, viral tropism was often limited 
to the tissue specificity of the host virus. Pseudotyping virions with 
the envelope glycoproteins of an alternative virus has served to 
somewhat resolve both of these issues. Witte et al. first showed that 
MLV gammaretroviruses could be successfully pseudotyped with 
the vesicular stomatitis virus glycoprotein (VSV-G) in 1977. This 
increased virion stability, improving titres, as well as substantially 
broadening tropism. In the mid-1990s, Miyanohara et al. demon-
strated that injection of VSV-G-pseudotyped MLV-based vector 
into the neonatal mouse liver resulted in strong marker gene expres-
sion with little expression in other organs [22]. Pseudotyping has 
become widely utilised as a process of increasing viral titre as well 
as broadening tropism (VSV-G, Ebola, Mokola and lymphocytic 
choriomeningitis virus G protein (LCMV) [23] or targeting specific 
tissue-types in vivo (influenza HA to the lung, rabies virus glyco-
protein to neurons) although many still retain a strong liver tropism. 
Interestingly, pseudotyping with the gp64 envelope protein of the 
insect baculovirus, Autographa californica, confers increased hepa-
tocyte tropism [24] highlighting both the flexibility but equally the 
complexities underlying viral pseudotyping. 
  Such principle advances have enabled the efficacy of gam-
maretroviruses and lentiviruses as gene transfer vectors in both 
animal and human studies, as have further vectorological manipula-
tions outlined with reference to specific vectors below. Concur-
rently, this has necessitated parallel progress in terms of safety, 
especially when using vectors based on human pathogens such as 
HIV-1. 
2.2.1. Gammaretroviruses 
  Gammaretroviruses, near universally represented by MLV 
based vectors, were first successfully used to transduce mouse he-
matopoietic progenitor cells capable of partially reconstituting bone 
marrow in vivo after positive selection of a marker transgene by 
Eglitis et al. in 1985 [25]. These MLV vectors were gutted of all 
coding sequences and contained only viral Long Terminal Repeats 
(LTRs) and an RNA packaging signal. MLV gag/pol and the en-
dogenous MLV envelope were expressed in trans in producer cells. 
Since this seminal study, safety has been improved somewhat by 
introducing self-inactivating (SIN) LTRs and tropism increased by 
pseudotyping, largely with VSV-G [26]. Nevertheless the use of 
vectors pseudotyped with ecotropic, amphotropic and gibbon ape 
leukemia virus (GALV) is common. In practice today’s gamma 
retroviral vectors differ very little from those described in 1985. 
2.2.2. Lentiviral Vectors 
  HIV-1 based vectors have been by far the most commonly used 
lentiviral vector for gene transfer since the mid 1990s. They are 
reported to be able to transduce both dividing and non-dividing 
cells due to the nature of the viral integrase [27] and the presence of 
the central polypurine tract (cPPT) but early HIV vector formats 
transduced quiescent hepatocytes relatively poorly. However, in-
corporation of additional elements such as the woodchuck hepatitis 
virus post-transcriptional regulatory element (WPRE) enhanced 
vector production [28]. Lentiviral vectors have also been derived 
from equine infectious anemia virus (EIAV) [29], feline immunode-
ficiency virus (FIV) and simian immunodeficiency virus (SIV). A 
high tropism for liver has been demonstrated following intravenous 
injection into fetal mice with EIAV [30] and neonatal mice with 
FIV [31].  
2.2.3. Retroviral Integration 
  Although the efficient and persistent expression achieved by 
retroviral vectors can be partly ascribed to their ability to integrate 
into the host genome, the downside is that insertion of a transgene 
in the host genome in the vicinity of a tumor suppressor gene or 
proto-oncogene may result in a malignant transformation of the 
cell. Moreover, it has been shown that retroviruses do not integrate 
in a completely random manner. For example gammaretroviruses 
preferentially integrate into the 5’ flanking region of expressed 
genes near transcription start sites [32], whereas HIV vectors inte-
grate across the whole transcriptional unit. In response to the per-
ceived dangers of these vector systems, a generation of non-
integrating retroviral vectors have been developed. These vectors 
take advantage of the fact that following reverse transcription, in-
stead of integrating, the DNA can assume a circular episomal for-
mat containing either one or two LTRs [33]. This form is very sta-
ble and provides long term expression in postmitotic tissues.  To 
prevent integration from occurring vectors have been synthesised 
contain a variety of mutations including those at critical residues of 
the viral integrase and those in the nucleotides which mediate bind-
ing of the integrase to the vector genome [34]. Very recently, inte-
grase-deficient lentivirus vectors (IDLV), injected into adult mice, 
have been shown to result in long-term expression of human coagu-
lation factor IX and to induce strong and antigen-specific immune 
tolerance, despite being up to 15-fold less efficient than the inte-
grating format of the vector [35]. 
2.3. Adeno-associated Viral (AAV) Vectors 
  Adeno-associated virus is a member of the parvovirus family 
and is one of the smallest DNA viruses. Wild type adeno-associated 
virus serotype 2 contains a single-stranded linear stretch of DNA 
comprising two genes which encode four replication proteins and 
three capsid proteins. In the absence of helper adenovirus or herpes 
simplex virus, wild type AAV establishes latency by integrating 
into human chromosome 19. Vector derived from AAV virus is a 
“gutless” design in that all viral genes are replaced with vector pay-
load, flanked by inverted terminal repeats (ITR) which are the only 
elements necessary for packaging the gene of choice into the vector. 
AAV vectors have been reviewed by Greiger and Samulski [36]. 
AAV serotype 2 was the archetypal vector however, since then, 
numerous further serotypes have been identified and many more 
unique isolates have been derived from humans and nonhuman 
primates [37, 38]. The vector genome is a single-stranded DNA, 
therefore second strand synthesis and annealing are required to 
generate a double-stranded DNA which can serve as a transcription 
template [39]. Since this was thought to be a major rate-limiting 
step in AAV-mediated gene expression, efforts were made to gen-
erate self-complementary vectors. These vectors contain self-com-
plementary molecules of DNA that can refold into double-stranded 
DNA templates for expression once within the cell. They have 
shown to be between 5 and 140-fold more efficient than single-
stranded counterparts [40, 41]. However one disadvantage is that 
the AAV payload is approximately 4.7kb therefore a self-comple-
mentary AAV vector is limited to carrying a gene plus promoter of 
only around 2.3 kb. A second concern, in terms of liver gene trans-
fer, is that a recent report describes that self-comple-mentary vec-
tors induce a substantially stronger TLR9-mediated innate immune 
response compared to single-stranded format vector [42]. 
  Lipshutz and colleagues were early pioneers in using AAV to 
study gene transfer to the fetal or neonatal liver. In 2001, they used 
AAV2 to deliver the light-emitting protein luciferase to the perito-
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transduction of liver compared to other visceral organs such as 
spleen, kidney and intestine. Although expression, as measured by 
whole body bioluminescent imaging, declined approximately 1000-
fold in the first month, expression was still detectable at six months 
of age [43].  
  The efficiency that can be attained using AAV vectors was 
recently put to good use by Paulk and colleagues, working towards 
a major goal of gene therapy – gene repair as opposed to gene sup-
plementation. They used a mouse model of inherited tyrosinemia 
type I which carries a single point mutation rendering it deficient in 
fumarylacetoacetate hydrolase (FAH). This disease causes accumu-
lation of toxic metabolites in the liver and the renal proximal tubule 
and causes death to the specific affected cells. The mouse model is 
an accurate, telescoped model of the human disease and serves as 
an excellent model for gene repair as corrected hepatocytes have a 
survival advantage compared with untreated cells. The authors in-
jected AAV2 and AAV8 vectors carrying wild-type genomic se-
quence for repairing the mutant FAH gene into neonatal and adult 
mice. Gene repair was successful at both ages of administration 
using AAV2 and AAV8, though more effective with the latter [44]. 
2.4. Non-viral Gene Transfer 
  Oft-cited concerns over the use of viral vectors include inser-
tional mutagenesis (by retroviral vectors), immunogenicity of viral 
components and limitations in vector payload size. This has, his-
torically, motivated development of non-viral vectors in which 
DNA is delivered using polymers, polycations and liposomes either 
singly or, sometimes, in combination. A major failing of many non-
viral gene therapy protocols has been the rapid elimination of ex-
pression as a consequence of gene silencing or dilution due to a 
lack of integration. Nevertheless, some studies have shown that 
with thoughtful incorporation of promoter and regulatory elements, 
long-term expression of luciferase marker gene [45] and the thera-
peutically relevant transgenes factors VIII and IX [46] can be 
achieved in adult mice following rapid, high volume intravenous 
injection. More recently, Wong and colleagues achieved strong, 
albeit transient, levels of marker gene expression under the control 
of the human -1-antitrypsin promoter in hepatocytes of neonatal 
immune competent mice using polyethylenimine (PEI) as the deliv-
ery agent [47].  
3. DISEASE TARGETS FOR FETAL AND NEONATAL 
GENE THERAPY 
3.1. Coagulation Disorders - Hemophilias A and B 
  The liver produces many of the factors of the coagulation cas-
cade including; fibrinogen (factor I), prothrombin (factor II), factors 
V, VII, VII, IX, X and IX, protein C and antithrombin [48, 49]. 
This cascade comprises a series of proteases and cofactors which 
control the generation of fibrin and thus, permits blood clotting at 
sites of injury but maintains an anti-coagulant state in the absence 
of vessel injury [50]. Mutations in the X-linked genes encoding 
coagulation factors VIII and IX are responsible for hemophilias A 
and B, respectively. Patients suffer from recurrent haemorrhage 
particularly into muscles and joints. The latter ultimately can lead to 
inflammation of the synovium and degenerative arthritis of one or 
more joints; the disease affects nearly half a million people in the 
world. In developed countries current treatment involves injection 
of the missing coagulation factor. These were initially obtained by 
plasma cryoprecipitiation but blood contaminated with HIV and 
hepatitis virus resulted in infections that devastated the hemophilia 
community. Over the past two decades recombinant coagulation 
factor protein has been used. Although this treatment has resulted in 
a great improvement in quality and duration of life, recombinant 
factor is incredibly expensive, has a relatively short half-life requir-
ing administration two or three times weekly and is not readily 
available in developing countries. Continual protein replacement 
does not completely abolish the prospect of developing hemophilic 
arthritis. Moreover, a significant proportion of patients develop 
inhibitory antibodies against the injected protein which puts them at 
grave risk of fatal hemorrhage [51]. Many preclinical studies have 
been performed in small and larger animal models for treatment of 
hemophilia. Moreover, several of these studies have resulted in 
clinical trials [52]. AAV vectors, which have a strong tropism for 
liver, have shown the greatest promise for clinical application. 
AAV2 delivery to humans with severe hemophilia B resulted in 
expression of therapeutic factor IX concentrations for up to eight 
weeks [53] before an anti-capsid immune response eliminated those 
hepatocytes that had been infected with the AAV vector [54]. In a 
separate series of studies, self-complementary AAV8 containing 
human factor IX under the control of a synthetic liver-specific pro-
moter was shown to establish prolonged high levels of gene expres-
sion when administered to mice and non-human primates [55]. This 
vector has been applied recently in a clinical trial where expression 
in one patient has risen from baseline to 1.5-2% and has maintained 
this level for more than 5 months [56].  
  The justification for treating hemophilia in the womb or in the 
neonatal period may not be immediately apparent; only rarely do 
newborns suffer life-threatening extracranial or intracranial bleed-
ing [57] and this is generally managed well using coagulation factor 
supplementation once diagnosis is confirmed. However, the mean 
age at which children with severe haemophilia experience their first 
bleed into a joint is 23 months [58], most likely because they be-
come highly active and mobile and, therefore, begin to exert in-
creased pressure on joints. Once joint damage has occurred as a 
result of recurrent bleeding, secondary prophylaxis can limit, but 
not prevent ongoing joint damage. This, therefore, vindicates a 
strategy for very early treatment. Retrospective analyses have re-
vealed that regular prophylaxis with coagulation factors is able to 
reduce physical impairment from hemophilia arthropathy [59]. 
Moreover, there is evidence that early commencement of prophy-
laxis and the avoidance of intensive treatment periods may reduce 
the risk of inhibitor development in the patient [60].  
  Ponder and colleagues have performed numerous and extensive 
studies on the delivery of factors VIII and IX during the neonatal 
period using gene therapy. In an early study, neonatal mice received 
intravenous injection of an MLV gamma retroviral vector express-
ing canine factor IX. This resulted in >100% normal levels of ex-
pression (5 g/ml) for up to a year. The same vector, injected into 
three newborn hemophilia B dogs resulted in cFIX expression of 
between 12-36% [61]. In an advancement of this study, the same 
group demonstrated that neonatal FIX delivery by retrovirus in-
duced immune tolerance to the transgenic protein and that this was 
dependent upon having gene expression above a threshold. Toler-
ance was demonstrated by challenging the neonatally-injected mice 
with FIX protein [62]. The group then turned their attention to de-
livery of canine B domain-deleted factor VIII to neonatal mice and 
dogs.  Hemophilia A mice and dogs expressed cFVIII concentra-
tions of 139% and 116% of normal values for more than 18 months; 
no anti-cFVIII antibodies were detected [63]. However, mirroring 
their FIX study, they observed that higher titres of FVIII retrovirus 
vector resulted in immune tolerization whereas mice which re-
ceived low doses of vector developed antibodies before or after 
challenge with FVIII protein [64]. In an earlier study, Vanden-
driessche and colleagues had employed an MLV gamma retroviral 
vector to deliver human factor VIII to neonatal hemophilia A mice. 
They observed prolonged FVIII production in 6 out of 13 mice 
injected for up to at least 14 months and four of the mice expressed 
physiological or supraphysiological concentrations of FVIII. Inter-
estingly, those that did not express FVIII developed anti-FVIII 
antibodies [65].  
  Fetal or neonatal gene delivery of factors VIII and IX has not 
been limited to gamma retroviral vectors. We demonstrated that 
HIV-1 based lentiviral vectors could be used to deliver human fac-
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the circulation via the vitelline vessel. This resulted in 9-16% levels 
of normal human factor IX levels in the circulation for up to at least 
14 months. Coagulation assays demonstrated near-normal levels of 
clotting function [66]. Very recently we used a lentiviral vector 
expressing a codon-optimised human factor VIII cDNA sequence to 
cure neonatal hemophilia A mice following intravenous injection 
by the superior temporal vein (Fig. 1b). Eighteen mice which re-
ceived different variants of FVIII expression cassette expressed 
>200% normal levels of human factor VIII for up to at least 250 
days [67]. 
  The use of gamma retroviral or lentiviral vectors would seem 
highly appropriate for gene delivery to the fetal or neonatal liver 
since the vector genomes integrate and, therefore, multiply in parity 
with the large increase in cell number in the growing liver. How-
ever, concerns over retrovirus-associated haematopoietic malignan-
cies arising in the X-SCID clinical trial [68] and EIAV lentivirus-
associated hepatocellular carcinoma following administration to 
fetal and neonatal mice [23] vindicates the application of epi-
somally maintained vector formats. One of the rationales underly-
ing the use of these vectors is that very early gene expression may 
facilitate induction of immune tolerization to the transgenic protein 
and that a booster injection of gene therapy vector could be per-
formed once the liver was approaching or had achieved its adult 
mass.  
  In 1999 Lipshutz and colleagues used a second-generation ade-
noviral vector to deliver mouse factor VIII to the fetal hemophilia A 
mouse by intraperitoneal injection at D15 gestation. They observed 
expression of 50% normal levels of mouse FVIII in the circulation 
2 days after birth but this declined rapidly to undetectable levels by 
21 days [69]. We administered a helper-dependent adenovirus vec-
tor to deliver hFVIII to the fetal (non-hemophilic) mouse at 15 days 
gestation. We measured relatively high expression, of 20% normal 
human levels, ten days after injection however this declined to 
nearly undetectable levels 37 days after injection [70]. Lipshutz and 
colleagues revisited this concept recently, administering helper-
dependent adenovirus to neonatal hemophilia A mice to deliver 
human factor VIII. Three days after injection hFVIII concentrations 
reached 649% of normal human levels yet, again, declined rapidly 
in the first 28 days of life. However, thereafter, levels stabilised to 
around 4% for the following 16 months. This expression was suffi-
cient to induce and maintain immune tolerization to human factor 
VIII and permitted a booster injection to these mice in adulthood, 
resulting in high (40%) and sustained (>3 months) expression of 
the clotting protein [71]. 
  In 2002 we used an AAV2 vector to deliver human factor IX to 
the liver of fetal mice by injection via the vitelline vessel. At that 
time the available titres of AAV were such that very low concentra-
tions of human factor IX (<1%) could be detected in mouse plasma 
ten days after injection [72]. Fortunately, in the subsequent years 
AAV-mediated gene delivery to the fetal or neonatal liver has been 
applied to much better effect. Sabatino and colleagues performed an 
elegant study where they injected AAV1 and AAV2, carrying hu-
man factor IX, to fetal, neonatal and adult mice. Fetal or neonatal 
administration of AAV1 was able to induce immune tolerance to 
human coagulation factor [73]. Very recently we have administered 
self-complementary AAV8 carrying human FIX (the same as is 
currently being used in the clinical trials mentioned above [56]) to 
mice at D15 gestation. Consistent with the other studies, we ob-
served a dramatic loss in gene expression from >65% of normal 
hFIX levels on the day of birth to undetectable levels at around 80 
days. Interestingly, hFIX expression began to re-appear at 200 days 
and up to at least 450 days [56].  
  This same vector has also been studied in larger animals. Sheep 
provide a useful model of human pregnancy; they have a consistent 
gestation of 145 days and the development of the fetus, particularly 
the immune system, is similar to that in humans. Using ultrasound 
guidance it has been feasible to administer gene transfer vectors to 
the circulation of the fetal sheep at different gestational ages [1]. 
Recently, David and colleagues administered AAV8-hFIX to early 
(around 60 days) and late (around 100 days) gestation fetuses. Fol-
lowing late gestation injections, blood concentrations of hFIX were 
particularly high, exceeding 30% of the concentration found in 
normal humans. In two cases, even at six months hFIX expression 
was maintained at around 1%. No antibodies to either capsid or FIX 
were detected following vector administrations. However, an im-
mune response to hFIX was induced by immunising the lambs with 
FIX protein in combination with an immune (Freunds) adjuvant 
[74]. In a parallel study, Mattar et al. injected the same vector form, 
or one pseudotyped with serotype 5 capsid, to the late gestation 
fetal macaque and observed widespread liver transduction with both 
vectors. Although there was an initial dramatic fall in FIX expres-
sion, it was stably maintained at levels between 7 and 111% of 
normal levels for between 2 and 22 months. Anti-capsid antibodies 
could be detected after AAV5 delivery and less so following AAV8 
however these antibodies did not eliminate expression [75]. 
3.2. Coagulation Disorders - Early and Lethal 
  Unlike hemophilias A and B, mutations resulting in complete 
deficiency of some coagulation factors result in very severe, very 
early onset disease phenotypes.  
  Coagulation factor X plays a fundamental role in the coagula-
tion cascade. It associates with factor V on the cell membrane to 
form part of the prothrombinase complex that converts prothrombin 
to thrombin. Inherited factor X deficiency is rare and in clinical 
presentation is one of the most serious of the bleeding disorders. 
The more severe cases present at birth with bleeding from the um-
bilical stump or, more gravely, in the central nervous system [76]. 
Apart from lethality, in some cases these bleeds result in severe 
 
 
 
 
 
 
Fig. (1). a. Injection into the mouse fetus following laparotomy of the mother b. Injection into the circulation of the neonatal mouse via the superficial tempo-
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neurological sequelae such as paralysis, blindness and seizures [77]. 
In the late 1990s, a gamma retroviral vector was designed to carry 
human factor X under the control of the liver specific -1-
antitrypsin promoter. This was injected into adult rats and resulted 
in levels of expression of 10-43% in four rats. However, a partial 
hepatectomy was required to achieve efficient liver transduction 
and several rats generated anti-FX antibodies [78]. To overcome 
these hurdles the group administered AAV2-FX to neonatal mice. 
Although lower levels, of approximately 7%, were detected they 
were achieved without partial hepatectomy and persisted for more 
than 14 months with no evidence of immune response [79].  
  Coagulation factor VII interacts with tissue factor at the site of 
vascular injury to form a serine protease, FVIIa, which is pivotal for 
activation of coagulation. Therefore, congenital FVII deficiency, 
the most common autosomal recessive bleeding disorder, is charac-
terised by a bleeding diathesis that is extremely severe or lethal in 
at least 20% of patients with a homozygous or compound heterozy-
gous genotype. These individuals generally have plasma FVII activ-
ity below 1% of normal and commonly (approximately 60%) pre-
sent with life threatening haemorrhage within critical organs such 
as the central nervous system during the neonatal period although 
their in utero development is normal [80, 81]. Promising prelimi-
nary data has been generated from experiments using self-
complementary AAV5 vectors expressing human factor VII. Ultra-
sound-guided injection into the peritoneal cavity of three fetal ma-
caques at 0.9 years gestation conferred therapeutic expression of 
human FVII at the time of birth (20% of normal levels) with ex-
pression being maintained above 5% of normal levels for at least 2 
months postnatal [82]. 
 Deficiency  of  A Disintegrin And Metalloprotease with Throm-
bospondin (ADAMTS13) results in thrombotic thrombocytopenic 
purpura (TTP). More than 50% of humans with severe ADAMTS13 
deficiency present at birth and the disease is characterised with 
recurring hemolytic and thrombocytopenic crises. Cerebral vascular 
incidents frequently result in neurological damage and there is a 
high risk of kidney failure following massive hematuria during 
hemolytic crises. The first descriptions of inherited TTP, in 1953, 
included three affected siblings, two of which were born jaundiced 
and subsequently died of bowel bleeding and haemorrhage at 4 
days and 2 years of life. Plasma therapy, every 2-3 weeks, has 
formed the mainstay of treatment for many years. However, pa-
tients with long intervals between crises are not placed on regular 
plasma therapy yet occasionally suffer from central nervous system 
and renal involvement. Recombinant ADAMTS13 exists but is not 
used for clinical treatment [83], therefore early gene therapy may be 
a useful therapeutic approach. Niiya et al. used a lentiviral vector to 
deliver ADAMTS13 (and a truncated variant) to mice deficient in 
that gene. These mice have a prothrombotic phenotype character-
ised by the accumulation of excessively large von Willebrand Fac-
tor (vWF) multimers in the plasma and enhanced platelet-
endothelial cell adhesion. The authors injected vector at 8 and 14 
days gestation into the amniotic fluid and vitelline vessel respec-
tively, the latter being associated with a lower rate of fetal mortality 
and targeted transduction of liver tissue. Treated mice exhibited a 
reduction in the size of vWF multimers and a significant prolonga-
tion of ferric chloride-induced carotid arterial occlusion time [84].  
3.3. Urea Cycle Disorders 
  The urea cycle, a process of breakdown of amino acids and 
elimination of ammonia in the form of urea, takes place primarily in 
the liver and to a lesser degree in the kidney. Genetic disorders of 
the urea cycle typically manifest as high ammonia levels and dis-
turbed amino acid metabolism. There are six well-known defects of 
the urea cycle that are deficiencies of the enzymes arginase, or-
nithine transcarbamylase (OTC), arginosuccinate synthase, argino-
succinate lyase, carbamoyl phosphate synthase and N-acetyl-
glutamate synthase. Newborns with urea cycle disorders tend to 
have a normal birth weight but present within hours to days after 
birth with serious illness commencing with vomiting, lethargy and 
rapid breathing which then progresses to hyperammonemia-induced 
coma. Of those who survive this period through aggressive therapy, 
half die before school age and nearly all have severe developmental 
disabilities. These diseases are treated by severe protein restriction 
and administration of sodium benzoate and sodium phenylbutyrate 
which stimulates alternative nitrogen clearance mechanisms. How-
ever, patients are still prone to suffer intermittent bouts of hy-
perammonemia. Liver transplantation is a valid alternative to long 
term pharmaceutical intervention and dietary restriction that results 
in complete correction of the metabolic defect. However, it only 
halts but does not reverse the neurological damage. It has been 
shown that liver transplantation early in life is associated with im-
provement of neurological outcomes in children [85, 86]. Unfortu-
nately, due to technical limitations and shortage of size-matched 
donor livers, this approach is not widely available to neonatal or 
infant patients and the procedure bears considerable risk [87]. In 
addition to these factors, a further justification for development of 
early intervention gene therapy is the evidence that urea cycle de-
fects may cause neurological damage in utero. In one case, a neo-
nate born with OTC deficiency died at 17 days of age and post-
mortem analysis of the brain revealed lesions that, by their appear-
ance, were more than eight weeks old. In the absence of no prenatal 
event to account for these lesions it was likely they arose from the 
genetic defect. Although it might be expected that fetal metabolic 
insufficiencies should be compensated by maternal metabolism, in 
this case the mother was a carrier, therefore she may have had par-
tial OTC deficiency and was unable to compensate sufficiently for 
the fetal defect [88]. 
  In 1990, early in the history of preclinical gene transfer tech-
nology, it was reported that an adenoviral vector encoding rat OTC 
was injected into a mouse model of OTC deficiency. The vector, 
injected intravenously into 1 day old mice, partially corrected the 
metabolic defect; an increase in hepatic OTC activity was detected 
and urinary orotic acid was reduced. OTC transcripts were detect-
able a year after injection and one mouse expressed >50% normal 
levels at 15 months. OTC-deficient mice display a phenotype of 
sparse fur until weaning but adenovirus-OTC reversed this pheno-
type in some individuals. However, results were quite variable [89]. 
Six years later, Morsy and co-workers used an adenoviral vector to 
deliver human OTC to OTC-deficient mice by transcutaneous injec-
tion into the neonatal liver parenchyma. Urinary orotic acid was 
reduced and there was a moderate increase in enzyme activity. 
However, they also reported a dominant negative effect of the en-
dogenous mutant protein on the activity of delivered recombinant 
wild-type human protein. They suggested this was due to the forma-
tion of inactive enzyme heterotrimers containing mutant and wild 
type subunits [90].  
  Gene therapy in adult OTC-deficient mice has been signifi-
cantly more successful with long-term correction of the defect be-
ing reported in several studies using helper-dependent adenovirus 
[91, 92] and AAV [93] vectors. In a comparative study, Cunning-
ham and colleagues injected AAV vector into adult and neonatal 
OTC-deficient mice. Following adult delivery phenotypic correc-
tion was prolonged and complete. However, following neonatal 
delivery full metabolic correction was transient although modest 
levels of enzyme activity persisted into adulthood. The authors 
admitted that the severe form of the disease presents neonatally and 
that neonatal gene transfer would be greatly desirable [94]. 
  Although the majority of preclinical studies have been per-
formed using OTC-deficient mouse models, Gau and colleagues 
recently demonstrated proof-of-principle for correction of arginase 
deficiency. A helper-dependent adenoviral vector was used to de-
liver mouse arginase I to an arginase-deficient mouse model. A 
significant improvement in survival was noted, from 14 days in the 
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was believed that the mice ultimately succumbed to hyperam-
monemic crisis due to arginase levels falling to less than 10% as 
transduced cells were diluted out by the growing liver [95]. 
  An adenoviral vector was used to deliver human arginosucci-
nate synthetase to the mouse model deficient in this enzyme. Gene 
delivery extended the average lifespan of these affected mice from 
30 hours to 16 days. Liver enzyme activity was detected at 47% 
twenty-four hours after vector infusion, peaking at >80% of normal 
levels seven days later before decreasing to 20% within 3 weeks. 
Despite liver enzyme levels being nearly corrected the treated mice 
had retarded growth, suggesting that reconstitution of liver enzyme 
activity was insufficient to fully reverse the disease pathology. In-
volvement of other organs such as kidney was, therefore, suggested 
[96]. 
  It is apparent, from these studies, that correction of this class of 
genetic diseases requires substantial levels of activity, likely greater 
than 10% of normal levels. Given the failure to mediate correction 
of these diseases following neonatal adenovirus or AAV vector 
administration, it is somewhat surprising that there have been no 
studies using gamma retroviral or lentiviral vectors, or studies 
where there is sufficiently robust gene transfer using non-integ-
rating vectors to achieve a plateau of enzyme activity at physio-
logical levels.  
3.4. Organic Acidemia 
  Organic acidemia describes a group of diseases characterised by 
excretion of urinary non-amino organic acids. They usually arise 
from disruption of one of numerous steps in amino acid breakdown, 
particularly genetic deficiency in the relevant enzyme. In a some-
what similar pattern to urea cycle disorder, the infant is born well 
but presents with vomiting, poor feeding, lethargy, fitting and, ulti-
mately, coma and death [97-99]. This group of diseases includes 
maple syrup urine disease (deficiency in the branched chain keto 
acid dehydrogenase) [100], propionic acidemia (deficiency in 
propionyl-coenzyme A carboxylase) [101], methylmalonic acide-
mia (methylmalonyl coenzyme A mutase) and isovaleric acidemia 
(deficiency of isovaleryl-coenzymeA dehydrogenase).  
  For maple syrup urine disease, to minimise damage to the neo-
natal brain, detoxification by continuous blood exchange transfu-
sion, hemodialysis or hemofiltration must be performed urgently. 
The patient is then managed by a strict dietary regime. Although 
most patients are expected to survive and some attend regular 
schools, intellectual outcome is substantially below average and 
metabolic crises are not uncommon. For propionic and methyl-
malonic acidemia the prognosis is more grave, with more severe 
neurological outcomes and also pathological changes in the heart 
and kidneys [97].  
  In 2007, Chandler and Venditti used a second-generation ade-
noviral vector expressing the methylmalonyl coenzyme A mutase 
gene under the constitutive control of a CMV promoter to treat a 
mouse model of methylmalonic acidemia. They administered vector 
into neonates by transcutaneous liver injection and direct muscle 
injection. They demonstrated that intrahepatic delivery improved 
50% survival from less than 2 days to around 20 days. Some treated 
mice survived for over 7 months. Using an adenoviral vector in this 
model was important in order to achieve very rapid gene expression 
but the vector was also likely subject to loss of transient expression 
and/or promoter silencing which accounted for the relatively short-
term correction. Moreover, the authors observed general procedure-
related mortality after intrahepatic injection [102]. Three years 
later, the same group used an AAV vector containing a liver-
specific thyroxine-binding globulin promoter in the same model 
system. In this study they characterised the model using many more 
uninjected mice (58 versus 17 previously). They demonstrated 
much more effective correction with 5 out of 6 mice which had 
received 4x10
11 AAV genomes surviving for more than one year 
[103]. The improvement in survival compared with the adenoviral 
vector administered mice may be attributable to both the increased 
efficiency of transduction of the AAV vector and also the resistance 
to silencing of the thyroxine-binding globulin promoter compared 
with the CMV promoter. In 2008, Hofherr and colleagues generated 
both early generation and helper dependent adenoviral vectors, with 
or without polyethylene glycol modification, and AAV vectors, for 
delivery of propionyl-coenzyme A carboxylase into a mouse model 
of propionic acidemia. Untreated mice usually die within 36 hours 
of birth but the authors observed a modest, yet statistically signifi-
cant increase in lifespan following intraperitoneal injection of vec-
tor [104]. In 2011 the authors joined Chandler and Venditi in using 
an AAV vector containing a CMV/Chicken -actin promoter to 
deliver propionyl-coenzyme A carboxylase by direct intrahepatic 
injection. This team saw a dramatic improvement in survival, from 
less than 10 days (11 mice) to a 50% survival at 40 days with one 
mouse surviving up to at least 9 months. Significant concentrations 
of enzyme expression in the treated mice were also shown [101].  
3.5. Lysosomal Storage Diseases 
  Lysosomal disorders result from defective function of a specific 
protein that results in lysosomal accumulation of undegraded sub-
strate or products of catabolism that are unable to exit the lysosome. 
More than fifty lysosomal storage diseases are known, most of 
which are inherited in an autosomal recessive fashion. Lysosomes 
are present in all cells possessing nuclei and form part of a complex 
intracellular recycling system that consists of many degradation 
steps. Defects in lysosomal enzymes, cofactors or transport proteins 
may result in specific lysosomal storage disorders which can be 
classified and categorised by the types of storage material which 
accumulates. Many present in infancy or early childhood although 
some present with a very severe and very early phenotype, even 
sometimes in utero. Of the lysosomal storage diseases which pre-
sent early, one of the first clinical presentations is non-immune 
hydrops fetalis – the accumulation of fluid in two or more fetal 
compartments. A second clinical presentation is neonatal dysmor-
phism. This group of diseases is reviewed extensively by Wraith 
[105]. Although lysosomal storage diseases have an extremely var-
ied phenotype and may affect various organ systems including the 
nervous system, the haematopoietic system and muscle, numerous 
preclinical studies have demonstrated therapeutic efficacy from 
liver targeted gene therapy approaches. This success is partly based 
upon the application of the liver as a genetic factory for the produc-
tion of the missing enzyme and has shown greatest success in those 
diseases where enzyme replacement therapy is most efficacious.  
Mucopolysaccharidoses 
  A subcategory of lysosomal storage diseases which has re-
ceived particular attention from the gene therapy community are the 
mucopolysaccharidoses. This subcategory refers to a group of dis-
eases characterised to defects in degradation of mucopolysaccha-
rides or, more accurately, glycosaminoglycans. They include type I 
(Hurler syndrome), II (Hunter syndrome), III A,B,C and D (San-
filippo syndrome), IV A and B (Morquio syndrome), VI (Maro-
teaux-Lamy syndrome), VII (Sly syndrome), IX (Natowicz syn-
drome). Consistent observations within the mucopolysaccharidoses 
include increased activity of -hexosaminidase,  -glucosidase,  -
galactosidase and -glucuronidase within the liver and brain with 
decreased sialidase and N-acetylglucosaminyltransferase. These are 
reviewed by Clarke [106]. Recent technological developments have 
led to the production of enzyme replacement therapy for mucopoly-
saccharidoses types I, II and VI. Since the enzyme cannot cross the 
blood-brain barrier, improvement in central nervous system mani-
festations is not seen, although bone marrow transplantation has 
been shown to stabilise CNS pathology in some diseases such as 
Hurler Syndrome [107]. Both approaches have significant short-
comings; enzyme replacement therapy is very expensive (>300,000 
USD per patient per year) and bone marrow transplantation is both 
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a 15% risk of early death. Although the liver is affected the main 
organs affected are the brain, heart, bone and joints. Nevertheless 
the liver has been targeted by gene transfer to transmogrify it into a 
biofactory for synthesis of the deficient enzyme. Gene therapy of 
these diseases has been reviewed in detail by Ponder and Haskins 
[108]. The majority of gene transfer studies have been performed in 
mouse, cat and dog models of mucopolysaccharidoses I and VII, 
particularly in the neonatal period. Adenoviral vector has been used 
in neonatal mice deficient in mucopolysaccharidosis VII [109, 110]. 
AAV2 has been injected into neonatal mice with mucopolysaccha-
ridosis I [111] and neonatal MPS VII mice [112]. Alternative AAV 
pseudotypes have been adopted in more recent years. For example 
AAV8 was applied MPS II mice [113] albeit in adults, rather than 
neonates. An important study by Tessitore and colleagues used 
AAV8 for liver delivery and AAV1 for muscle delivery in neonatal 
MPS VII cats and rats. The authors concluded that gene expression 
in the liver was the most effective for disease correction [114]. 
Gamma retroviral vectors have been the most extensively applied 
for treatment of mucopolysaccharidoses, probably because the in-
terested research groups have extensive experience with this vector, 
but also likely because this strategy has proved very effective fol-
lowing neonatal gene transfer. Gamma retroviral vector has been 
used in neonatal MPS I mice [115, 116], neonatal cats [117] and 
fetal [118] and neonatal dogs [119]. This vector class has also been 
applied to neonatal MPS VII mice [120] and dogs [121-124]. An 
ex-vivo gene transfer and re-implantation of fetal liver cells to mice 
in utero has also been shown to provide a modest delay in patho-
logical changes [125].Whereas AAV vectors have resulted in a 
range of enzyme expression from 1% to 1700%, i.e. 17-fold over 
physiological concentrations, gamma retroviral vectors have 
achieve corrections as much as 500-fold over physiological concen-
trations. Achieving very high plasma concentrations appears to be 
important for cross-correction of systemic pathology of liver-
synthesised enzyme. 
  In response to concerns over safety of gamma retroviral vectors, 
there has been a move towards use of lentiviral vectors in the field 
of mucopolysaccharidosis research. For example Metcalf and col-
leagues employed a self-inactivating lentiviral vector for delivery of 
-L-iduronidase to MPS I mice. However, improvements were re-
ported to be less profound than when using a gamma retroviral 
vector with intact long terminal repeats, likely as a consequence of 
less efficient transduction and expression of the liver [126]. 
Fabry disease 
  Fabry disease is an X-linked disorder caused by deficiency in -
galactosidase. Undigested glycosphingolipids accumulate in endo-
thelial cells of kidney, heart and liver and symptoms include angi-
okeratoma, hypohidrosis and episodic pain crises in the extremities 
with the patient eventually dying of heart or kidney complications. 
Recombinant enzyme replacement therapy is the main treatment 
albeit at great financial cost and with immune involvement reducing 
efficacy . Ogawa and colleagues compared neonatal (2 days) and 
adult (12 weeks) gene therapy in a mouse model of Fabry disease 
using AAV1 vector carrying a CAG promoter. Adult gene transfer 
mainly targeted the liver whereas, following neonatal delivery, 
expression was concentrated in the heart [127]. In this disease, spe-
cific liver gene transfer may not be the preferred target. Further-
more, in this study, AAV1 was quite poor in transducing neonatal 
tissues therefore the principle advantage of injecting neonates with 
vector in this study was induction of immune tolerance rather than 
achieving widespread transduction of affected tissues. 
3.6. Glycogen Storage Diseases 
  The glycogen storage diseases (glycogenoses) comprise several 
genetic deficiencies of enzymes that control glycogen synthesis or 
catabolism of glycogen. Glycogen is mainly stored in the liver and 
muscle. Liver-based glycogen storage diseases, which result in 
hypoglycemia, include glycogen storage diseases Types 0, Ia, Ib, 
IIIa, IIIb, VI and IX [128]. Clinical manifestations vary depending 
upon the nature and extent of the deficiency. For example, Type I 
presents hepatomegaly, failure to thrive, hyperlactatemia, hyperu-
ricemia and hyperlipidemia. Type IV usually presents within 12 
months of birth as hepatomegaly and growth retardation and tends 
to progress to cirrhosis. Management is highly type-dependent but 
generally involves careful dietary control of glucose levels by glu-
cose infusion, protein feedings, uncooked cornstarch (a means of 
glucose slow release) [129].  
  Glycogen storage disease type Ia (also known as von Gierke 
disease) is deficiency of glucose-6-phosphatase. Infants usually 
present with seizures and hepatomegaly before a year of age. As per 
other glycogen storage diseases it is managed by glucose infusion 
and regular (every 3 to 6 hours) dietary uncooked cornstarch. De-
spite this management, long-term complications include growth 
failure, renal dysfunction, hypertension and hepatic adenomas that 
can progress to hepatocellular carcinomas. This disease has re-
ceived particular attention from gene therapy researchers and stud-
ies performed in the early 2000s are reviewed by Koeberl [130]; 
since only 15% of mice deficient in glucose-6-phosphatase survive 
until weaning at 21 days the majority of studies were, by necessity, 
very early interventions. However, it is possible to maintain them 
until weaning by twice daily intraperitoneal injection of glucose. 
Administration of early-generation adenoviral vector to 14-day old 
mice resulted in phenotypic rescue resulting in 90% survival at 84 
days of age, however, the authors recognised that expression from 
this vector was relatively short-lived and that although their results 
justified further research into gene therapy for this condition, early 
generation adenoviral vector may not be a suitable candidate for 
clinical application [131]. It is probably no co-incidence that this 
sentiment was raised at the same time that a fatality arising from 
gene therapy of ornithine transcarbamylase deficiency using early 
generation adenoviral vector was reported [132]. Sun and col-
leagues co-administered adenovirus and AAV2 vector to 1-2 day 
old mice by the superior temporal vein and saw correction of the 
genetic defect and survival beyond one year of age; the mice exhib-
ited normal plasma glucose, cholesterol, triglyceride and uric acid 
profiles. Interestingly, the authors surmised that the majority of 
correction could be attributed to the contribution of the AAV vector 
rather than the adenoviral vector. Nevertheless, the adenoviral vec-
tor provided the initial rapid ramping of gene expression that pre-
vented very early neonatal death. Ghosh and colleagues injected 
single-stranded AAV2/1 into the temporal vein of 1-2 day old 
knockout mice and some mice received a second infusion, of 
AAV2/1 or AAV2/8 at 1 week of age. The dual infusion strategy 
resulted in enzyme expression in liver and kidney for the full 57 
weeks of the study [133]. Similarly, Koeberl and colleagues in-
jected single-stranded AAV2/8 vector into 2-week old mice main-
tained on intraperitoneal glucose and demonstrated a dramatic in-
crease in survival beyond weaning once glucose had been with-
drawn [134]. However these studies from 2006 failed to correct, 
completely, blood glucose levels to those of wild type littermates 
and very high vector titres were used. Subsequently, Koeberl 
moved to AAV in a self-complementary format and achieved long-
term correction in mice with a 600-fold lower dose of vector. Cru-
cially, it prevented hypoglycemia during fasting in both the mouse 
and dog models although the dogs had elevated lactate concentra-
tions indicating that correction was not complete. Nevertheless, the 
study also demonstrated a substantial reduction in mortality in the-
dog model (after vector injection at 3 days of age) [135]. Weinstein 
and colleagues also demonstrated correction in dogs which received 
injection of AAV8 at 1 day of age and a second injection of AAV1 
at a later time point. In this study the dogs did achieve normal lac-
tate concentrations. However, results confirmed that a single neona-
tal injection of AAV8 is not enough to confer correction of glyco-
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  Most of the recent studies have utilised AAV vectors although 
not to complete exclusion of other vector types. Koeberl and col-
leagues also injected helper-dependent adenoviral vector into neo-
natal neonatal mice of a strain deficient in glucose-6-phosphatase. 
More than half of the treated mice survived beyond 28 weeks in 
comparison with the untreated group where all mice were dead by 5 
weeks of age [137]. In 2010, Feline Immunodeficiency Virus-based 
lentiviral vector was used to deliver glucose-6-phosphatase to mice 
deficient in this enzyme. A single neonatal injection corrected nei-
ther pathology nor biochemistry however a double neonatal injec-
tion protocol, at days 1 and 7, resulted in normalised blood glucose 
levels substantially extended survival and decreased storage mate-
rial in the liver. However treated mice still displayed hepatomegaly 
likely because transduction in the liver was patchy with some areas 
still showing accumulations of storage material [31]. 
  As a footnote, a distinction should be made between the afore-
mentioned glycogen storage diseases which mainly affect the liver 
and those which primarily affect the muscle and are reviewed else-
where [138]. It is also worth pointing out that one notable example 
of this distinction is glycogen storage disease type II, also known as 
Pompe disease, which also happens to be a lysosomal storage dis-
ease and which presents early in life. Unfortunately, the numerous 
preclinical studies for gene therapy of this disorder are beyond the 
remit of this liver-based review.  
3.7. Bile Metabolism 
  Polymorphisms in three genes involved in bilirubin metabolism 
have been identified as underlying neonatal hyperbilrubinemia. 
Although generally benign, in severe deficiencies plasma bilirubin 
concentrations rise to levels that may cause brain damage [139, 
140]. One of the more serious genetic defects is of the gene UDP-
glucuronosyltransferase 1A1 (UGT1A1). Crigler-Najjar type I dis-
ease (CN1) is an autosomal recessive syndrome which results in 
complete deficiency of the liver enzyme and subsequent unconju-
gated bilirubin accumulates in the brain resulting in neuropathology 
and may cause permanent disability. Current treatment is extensive 
phototherapy which is associated with skin abnormalities and can-
not completely prevent brain damage. Therefore, liver transplanta-
tion remains the only cure and the case for very early transplanta-
tion before the onset of CNS damage is strong [141].  
  Several studies describing fetal or neonatal gene transfer for 
preclinical models of Crigler-Najjar syndrome have been published. 
Seppen and colleagues used a lentiviral vector to deliver the gene to 
a rat model (Gunn rats) of Crigler-Najjar syndrome. Transcutaneous 
intra-hepatic injection of vector into the fetal liver resulted in long-
term partial reduction in serum bilirubin levels. Interestingly, ex-
pression was transient in the liver but persisted in other tissues 
which, the authors pointed out, was clearly sufficient to ensure 
prolonged gene expression [142]. Interestingly, in a subsequent 
study, they also observed an immune response against UGT1A1 
and suggested that it may be a particularly immunogenic protein 
[143]. However, the mode of delivery (intraparenchymal injection) 
may have caused some local tissue damage that precipitated an 
immune reaction that could be absent with intravascular delivery. In 
addition, it has been shown that hepatocyte-specific expression of 
transgene can result in immune tolerance to the protein [144]. 
Therefore, in achieving prolonged expression in tissues outside the 
liver but not in hepatocytes, this mechanism would not be triggered. 
Nguyen and colleagues also used a lentiviral vector for delivery 
into neonatal Gunn rats. In contrast to Seppen and colleagues, the 
vector was injected intravenously via the superior temporal vein 
and hepatocytes were observed to be the main source of expression. 
In this study, normalisation of bilirubin was achieved for up to at 
least 95 weeks [145]. The same group used an AAV8 vector to treat 
neonatal Gunn rats. In this case, serum bilirubin concentrations 
were only reduced transiently suggesting that this would not be a 
viable therapeutic approach.  
3.8. Immune Diseases 
  Two interesting studies have used gene delivery to the liver as a 
means of addressing immune system defects. In the first, Carbonaro 
and colleagues used an HIV-1 based lentiviral vector for expression 
of adenosine deaminase (ADA) in ADA-deficient mice following 
neonatal intravenous injection. ADA enzyme activity was signifi-
cantly lower in thymus and spleen than found in wild-type mice but 
was elevated between 2-10 fold in livers of treated mice compared 
with wild-types and 10-100 fold greater than found in the knock-
outs; proviral copy number was mainly detected in the liver. Im-
mune function was greatly improved by this strategy and the 
authors surmised that the lymphoid system may have been rescued 
in trans by metabolic effects of ectopic ADA expression. They 
suggested that the liver was acting as a ‘sink’ for degradation of 
deoxyadenosine and adenosine nucleosides or that circulating 
ADA, likely secreted by the liver, was being distributed systemi-
cally [146]. In the second study, Spitzer and colleagues used 
gamma retroviral vectors in the treatment of a mouse model defi-
cient in C receptor 1-related gene/protein y (Crry). They designed 
and delivered a retroviral vector expressing Crry with single chain 
antibody fragment which ensured that secreted Crry could attach to, 
and correct the deficiency on the surface of red blood cells. They 
demonstrated that this strategy was able to correct the complement 
activation defect in these mice for up to at least a year [147], illus-
trating the concept of using the liver as a protein factory. 
4. CHALLENGES AND PERSPECTIVES 
4.1. Genotoxicity and Oncogenicity Risks of Early Gene Trans-
fer 
  There is some evidence that gene transfer in the fetal or neona-
tal period engenders a higher risk of genotoxicity or even malignant 
transformation. We observed a high incidence of hepatocellular 
carcinomas and the occurrence of metastatic events following fetal 
and neonatal intravenous, intramuscular and intraspinal injection of 
EIAV-based lentivirus vector for delivery of -galactosidase and 
human factor IX [23]. We have observed a high incidence of tumor 
formation following fetal intravenous injection with FIV-based 
lentivirus in some (unpublished observations) but not all studies 
[31]. However, to date, following several studies where many mice 
were injected in utero and neonatally by these routes with HIV-
based lentivirus we have observed no increase, over background, in 
the incidence of hepatocellular carcinoma [34, 67, 148]. Tittiger 
and colleagues also observed no increase in oncogenesis following 
early gene transfer of gamma retrovirus vectors [149] 
  Studies by Donsante and colleagues have also reported a high 
incidence of hepatocellular carcinoma in AAV-treated mice with 
lysosomal storage disease [150] and have implicated insertional 
mutagenesis as the causative mechanism [151]. However several 
subsequent studies have failed to observe tumor formation follow-
ing neonatal delivery of AAV vectors at very high titres into neona-
tal or fetal mice [152-154]. 
4.2. Advantages and Disadvantages of Fetal and Neonatal Gene 
Transfer to the Liver 
  The advantages of early liver gene transfer (or, to any other 
organ system) have been restated in numerous reviews and pub-
lished studies over the past decade or more on fetal [1, 2, 73] and 
neonatal [71, 155] gene transfer. Firstly, since the fetal or neonatal 
organism is small and contains much fewer cells it is possible to 
achieve a much higher vector:cell ratio with early intervention. 
Secondly, stem cell and/or progenitor populations are likely much 
more accessible early in life due to their abundance and their physi-
cal placement in the developing tissues/organs. Thirdly, early gene 
transfer and, thus, expression may predispose the immune system 
towards immune tolerance of the expressed xenoprotein; as Billing-
ham, Brent and Medawar demonstrated in the early 1950s; the de-
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tolerant to self antigens [156]. One of the major hurdles facing adult 
gene therapy is the development of an immune response that elimi-
nates transgene expression. However, there are numerous aspects to 
this response and the advantage which early gene transfer provides. 
Early transgene expression may persuade the immune system that 
the expressed protein is “self”. A de novo immune response to cap-
sid proteins, such as seen in the recent adult trial for hemophilia B 
[54] may be avoided since the neonatal adaptive immune response 
is thought to be relatively poor [157]. The individual may have 
been exposed to antigenic epitopes of the wild-type virus from 
which the vector is derived. This would be avoided by early gene 
transfer to a recipient whose immune system was almost completely 
naive to infection. The fourth and, likely, most important advantage 
of early intervention is that it could prevent or ameliorate the onset 
of early and irreversible pathological changes.  
  The area of fetal and neonatal gene transfer to the liver (and 
other organ systems) faces several conundrums.  
  Firstly, is the question of whether gene transfer before birth 
would ever be carried out in preference to postnatal intervention. 
This would depend upon several things. For diseases where patho-
logical changes occur later in infant life, for example hemophilia, 
neonatal gene transfer may be adequate. However other diseases, 
such as severe Protein C deficiency [158] and OTC deficiency [88], 
may manifest severe pathology even before birth. In these cases it 
would be essential to intervene before pregnancy had come to term: 
One alternative to in utero intervention would be elective early 
delivery and injection into the neonate. An interesting article by 
Pollock-BarZiv describes 26 fetuses that were diagnosed with pro-
found heart defects and were listed as amenable for heart transplan-
tation. Two of these fetuses were surgically delivered at 36 weeks 
gestation when a donor organ became available and were trans-
planted within the first six hours of life [159]. A second considera-
tion is the fundamental changes that occur in the liver from fetal to 
neonatal life. In humans hematopoiesis in the liver peaks around 22 
weeks gestation which then declines thereafter as the liver gradually 
assumes its phenotype of postnatal life; in mice it peaks at 14.5 
days gestation [160]. Since the fetus gains nutrients from the pla-
centa, portal circulation from the intestines to the fetal liver is less 
important than in adult life and the ductus venosus acts as a shunt 
permitting a substantial fraction (20-50%) of umbilical blood flow 
to bypass the liver and to be delivered directly to the heart. At birth 
profound circulatory changes induce closure of this vessel [161]. 
Whether either the hematopoietic or circulatory differences between 
the fetal and neonatal liver are relevant to efficacy of gene targeting 
is debatable. Unless injected as an asanguinous bolus, vector parti-
cles might be expected to transduce cells with cognate receptors 
over several passes through the entire circulation. Similarly there is 
no evidence to suggest that hematopoietic cells populating the fetal 
liver are any more amenable to transduction than when they assume 
residence in the bone marrow where they remain through postnatal 
life.  
  A second question relates to the issue of whether serious ge-
netic diseases could ever be diagnosed early enough to provide 
prophylactic gene therapy. For families with affected siblings ge-
netic screening would be feasible. However, in many cases the 
underlying cause is a de novo mutation. An interesting perspective 
is provided in a study by Hayes and colleagues of adults and of 
parents of individuals with mucopolysaccharidoses. They con-
ducted a survey to assess hypothetical clinical scenarios about new-
born screening for mucopolysaccharidosis which is now technically 
possible. Ninety-seven percent supported the use of newborn 
screening in situations where early treatment for the disease was 
available but 87% supported newborn screening for severe muco-
polysaccharidosis where no treatment was available. The most 
common reason cited for this was that newborn screening could 
avoid the stress of delayed diagnosis [162]. 
  A third question is, “Which is the best vector?”. It has become 
apparent that each vector has core strengths and applications for 
clinical gene therapy of adult patients. For example, AAV has been 
the most effective in topical delivery to the retina for inherited 
blindness [163-165] and also for liver-targeted treatment of hemo-
philia [53, 56]. Gamma retroviral and lentiviral vectors have per-
formed well for ex vivo gene therapy of hematopoietic stem cells 
for treatment of X-SCID [166], ADA-SCID [167] and X-linked 
Adrenoleukodystrophy [168]. Adenovirus has been applied exten-
sively for anti-cancer therapy. A summary of selected current gene 
therapy clinical trials, categorised by vector is provided by Sheridan 
[169]. For neonatal gene therapy of the liver several factors need to 
be considered. The opinion of these authors is that adenovirus vec-
tor in either a first or second generation format or even a helper-
dependent format is unlikely to be first choice for treatment of an 
inherited liver disease. Concerns over immune responses towards 
capsid proteins following systemic adenovirus delivery remain even 
though these barriers have been shown to be surmountable in a 
preclinical setting [170]. Therefore the choice is between retroviral 
vectors (including lentivirus vectors) and AAV. The increase in 
mass of the human liver is relatively linear from 12-34 weeks gesta-
tion but around birth demonstrates an upswing in growth [171] 
likely representing the acquisition of metabolic responsibility con-
comitant with loss of maternal metabolic support at birth. Therefore 
retrovirus, which integrates into the host genome, should maintain 
parity of expression with host proteins as the liver grows. In con-
trast AAV vector, which is generally considered to be episomally 
maintained, should be diluted out during rapid cell proliferation in 
the maturing liver. As shown in Fig. 2, the mouse liver has reached 
nearly maximum mass by 70 days of age whereas other organs such 
as lung and kidney as well as whole body weight are still increas-
ing. Similarly in the early neonatal period in humans there is a rela-
tively large increase in liver mass compared with other organs 
[171]. These phenomena are highlighted eruditely in the compari-
son of vectors reviewed by Ponder and Haskins [108]. They are 
also demonstrated clearly in fetal and neonatal studies using AAV 
and lentivirus vectors: When lentivirus was used for fetal and neo-
natal treatment of hemophilias A [67] and B [66], respectively, 
plasma coagulation factor concentrations remained relatively steady 
despite a huge increase in liver mass in the first hundred days of 
life. In contrast, AAV vectors applied to mice [152], sheep [74] and 
non-human primates [75] resulted in a dramatic loss of expression. 
In mice this loss was near total whereas in non-human primates the 
levels fell to levels that remained at physiological concentrations in 
one individual. For hemophilia, a residual concentration of even 
>1% would convert a severe hemophilia into one classified as mod-
erate and >5% would be classified as mild [172] therefore neonatal 
AAV might suffice. In contrast, gene therapy for mucopolysaccha-
ridosis type I may require several-hundred fold increase (over nor-
mal) in enzyme activity, secreted by the liver, to correct the sys-
temic defect [108] and this may only be achievable using gamma 
retroviral vectors. Ultimately, success of AAV in adult clinical trial 
for systemic gene therapy is likely to be the strongest vindication of 
candidacy as a viable vector for fetal or neonatal gene transfer. Yet 
the efficiency of AAV to cross vascular and cellular barriers may 
yet, for fetal gene transfer, have unwanted side effects. Mattar and 
colleagues have demonstrated, following AAV8 and AAV5 ad-
ministration to fetal macaque, transplacental transfer from fetus to 
mother [75].  
5. ENDNOTE 
  The numerous and recent references cited in this review illus-
trate and emphasise that the technology for treating serious genetic 
liver diseases is reaching maturity and fetal or neonatal application 
of this technology is both feasible and necessary. The Titan Prome-
theus, of Greek mythology, was known as champion of mankind 
who gave the Zeus’ fire to the mortals. Zeus punished him by tying 
him to a rock; a huge eagle tore out his liver every day but every Perinatal Gene Transfer to the Liver  Current Pharmaceutical Design, 2011, Vol. 17, No. 24    2537 
night it grew back, to be eaten again the following day [173]. Re-
cent advances in technology give us hope that we may soon have 
genetic therapeutic interventions for the most devastating of dis-
eases which beset the liver. Combating liver-munching eagles with 
gene therapy may take a little more time. 
  As a final note it is with regret that through space concerns we 
have omitted many other important studies and we would like to 
apologise to the authors of these studies. 
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Fig. (2). Whole body weight and mass of liver, lung and kidney in MF1 outbred mice in the first 150 days of life. 
Whole body
M
a
s
s
 
(
g
)
M
a
s
s
 
(
g
)
50 100 150
20
0
40
60
Liver
0 0 50 100 150
1
0
2
3
4
Lung
0 50 100 150
0.1
0 0
0.2
0.3
0.4
0.5
Age(days)
Kidney
50 0 100 150
0.2
0.4
0.6
Age(days)2538    Current Pharmaceutical Design, 2011, Vol. 17, No. 24  McKay et al. 
[15]  Alba R, Bradshaw, AC, Coughlan, L, et al. Biodistribution and 
retargeting of FX-binding ablated Ad5 vectors. Blood 2010; 116: 
2656-2664. 
[16]  Cerullo V, Pesonen, S, Diaconu, I, et al. Oncolytic adenovirus 
coding for granulocyte macrophage colony-stimulating factor 
induces antitumoral immunity in cancer patients. Cancer Res 2010; 
70: 4297-309. 
[17]  Small EJ, Carducci, MA, Burke, JM, et al. A phase I trial of 
intravenous CG7870, a replication-selective, prostate-specific 
antigen-targeted oncolytic adenovirus, for the treatment of 
hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 
107-17. 
[18]  Alba R, Bosch, A, Chillon, M. Gutless adenovirus: last-generation 
adenovirus for gene therapy. Gene Ther 2005; 12 Suppl 1: S18-27. 
[19]  Suerth JD, Maetzig, T, Galla, M, Baum, C, Schambach, A. Self-
inactivating alpharetroviral vectors with a split-packaging design. J 
Virol 2010; 84: 6626-35. 
[20]  Trobridge GD, Miller, DG, Jacobs, MA, et al. Foamy virus vector 
integration sites in normal human cells. Proc Natl Acad Sci USA 
2006; 103: 1498-503. 
[21]  Baum C, Schambach, A, Bohne, J, Galla, M. Retrovirus vectors: 
toward the plentivirus? Mol Ther 2006; 13: 1050-63. 
[22]  Miyanohara A, Yee, JK, Bouic, K, LaPorte, P, Friedmann, T. 
Efficient  in vivo transduction of the neonatal mouse liver with 
pseudotyped retroviral vectors. Gene Ther 1995; 2: 138-42. 
[23]  Themis M, Waddington, SN, Schmitt, M, et al. Oncogenesis 
following delivery of a non-primate lentiviral gene therapy vector 
to fetal and neonatal mice Mol Ther 2005; 12: 763-771. 
[24]  Kang Y, Xie, L, Tran, DT, et al. Persistent expression of factor 
VIII in vivo following nonprimate lentiviral gene transfer. Blood 
2005. 
[25]  Eglitis MA, Kantoff, P, Gilboa, E, Anderson, WF. Gene expression 
in mice after high efficiency retroviral-mediated gene transfer. 
Science 1985; 230: 1395-8. 
[26]  Burns JC, Friedmann, T, Driever, W, Burrascano, M, Yee, JK. 
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral 
vectors: concentration to very high titer and efficient gene transfer 
into mammalian and nonmammalian cells. Proc Natl Acad Sci 
USA 1993; 90: 8033-7. 
[27]  Naldini L, Blomer, U, Gallay, P, et al. In vivo gene delivery and 
stable transduction of nondividing cells by a lentiviral vector. 
Science 1996; 272: 263-7. 
[28]  VandenDriessche T, Thorrez, L, Naldini, L, et al. Lentiviral vectors 
containing the human immunodeficiency virus type-1 central 
polypurine tract can efficiently transduce nondividing hepatocytes 
and antigen-presenting cells in vivo. Blood 2002; 100: 813-22. 
[29]  Olsen JC. Gene transfer vectors derived from equine infectious 
anemia virus. Gene Ther 1998; 5: 1481-7. 
[30]  Waddington SN, Mitrophanous, KA, Ellard, F, et al. Long-term 
transgene expression by administration of a lentivirus-based vector 
to the fetal circulation of immuno-competent mice. Gene Ther 
2003; 10: 1234-40. 
[31]  Grinshpun A, Condiotti, R, Waddington, S, et al. Neonatal gene 
therapy of glycogen storage disease type Ia using a feline 
immunodeficiency virus based vector. Mol Ther 2010; 18: 1592-
1598. 
[32]  Wu X, Li, Y, Crise, B, Burgess, SM. Transcription start regions in 
the human genome are favored targets for MLV integration. 
Science 2003; 300: 1749-51. 
[33]  Banasik MB, McCray, PB, Jr. Integrase-defective lentiviral 
vectors: progress and applications. Gene Ther 2010; 17: 150-7. 
[34]  Apolonia L, Waddington, SN, Fernandez, C, et al. Stable Gene 
Transfer to Muscle using Non-Integrating Lentiviral Vectors. Mol 
Ther 2007; 15: 1947-1954. 
[35]  Matrai J, Cantore, A, Bartholomae, CC, et al. Hepatocyte-targeted 
expression by integrase-defective lentiviral vectors induces 
antigen-specific tolerance in mice with low genotoxic risk. 
Hepatology 2011; 53: 1696-707. 
[36]  Grieger JC, Samulski, RJ. Adeno-associated virus as a gene therapy 
vector: vector development, production and clinical applications. 
Adv Biochem Eng Biotechnol 2005; 99: 119-45. 
[37]  Gao G, Vandenberghe, LH, Alvira, MR, et al. Clades of Adeno-
associated viruses are widely disseminated in human tissues. J 
Virol 2004; 78: 6381-8. 
[38]  Gao G, Alvira, MR, Somanathan, S, et al. Adeno-associated 
viruses undergo substantial evolution in primates during natural 
infections. Proc Natl Acad Sci USA 2003; 100: 6081-6. 
[39]  Nakai H, Storm, TA, Kay, MA. Recruitment of single-stranded 
recombinant adeno-associated virus vector genomes and 
intermolecular recombination are responsible for stable 
transduction of liver in vivo. J Virol 2000; 74: 9451-63. 
[40]  McCarty DM, Fu, H, Monahan, PE, et al. Adeno-associated virus 
terminal repeat (TR) mutant generates self-complementary vectors 
to overcome the rate-limiting step to transduction in vivo. Gene 
Ther 2003; 10: 2112-8. 
[41]  McCarty DM, Monahan, PE, Samulski, RJ. Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote 
efficient transduction independently of DNA synthesis. Gene Ther 
2001; 8: 1248-54. 
[42]  Martino AT, Suzuki, M, Markusic, DM, et al. The genome of self-
complementary AAV vectors increases TLR9-dependent innate 
immune responses in the liver. Blood 2011. 
[43]  Lipshutz GS, Gruber, CA, Cao, Y, et al. In utero delivery of adeno-
associated viral vectors: intraperitoneal gene transfer produces 
long-term expression. Mol Ther 2001; 3: 284-92. 
[44]  Paulk NK, Wursthorn, K, Wang, Z, et al. Adeno-associated virus 
gene repair corrects a mouse model of hereditary tyrosinemia in 
vivo. Hepatology 2010; 51: 1200-8. 
[45]  Argyros O, Ping Wong, S, Niceta, M, et al. Persistent episomal 
transgene expression in liver following delivery of a 
scaffold/matrix attachment region containing non-viral vector. 
Gene Ther 2008; 15: 1593-1605. 
[46]  Miao CH, Ye, X, Thompson, AR. High-level factor VIII gene 
expression in vivo achieved by nonviral liver-specific gene therapy 
vectors. Hum Gene Ther 2003; 14: 1297-305. 
[47]  Wong SP, Argyros, O, Howe, SJ, Harbottle, RP. Systemic gene 
transfer of polyethylenimine (PEI)-plasmid DNA complexes to 
neonatal mice. J Control Release 2011; 150: 298-306. 
[48]  Biron-Andreani C, Bezat-Bouchahda, C, Raulet, E, et al. Secretion 
of functional plasma haemostasis proteins in long-term primary 
cultures of human hepatocytes. Br J Haematol 2004; 125: 638-46. 
[49]  Tatsumi K, Ohashi, K, Taminishi, S, et al. Regulation of 
coagulation factors during liver regeneration in mice: Mechanism 
of factor VIII elevation in plasma. Thromb Res 2011; In Press. 
[50]  Hoffman MM, Monroe, DM. Rethinking the coagulation cascade. 
Curr Hematol Rep 2005; 4: 391-6. 
[51]  Petrus I, Chuah, M, Vandendriessche, T. Gene therapy strategies 
for hemophilia: benefits versus risks. J Gene Med 2010; 12: 797-
809. 
[52]  High KA. Update on progress and hurdles in novel genetic 
therapies for hemophilia. Hematology Am Soc Hematol Educ 
Program 2007; 2007: 466-72. 
[53]  Manno CS, Arruda, VR, Pierce, GF, et al. Successful transduction 
of liver in hemophilia by AAV-Factor IX and limitations imposed 
by the host immune response. Nat Med 2006; 12: 342-347. 
[54]  Pien GC, Basner-Tschakarjan, E, Hui, DJ, et al. Capsid antigen 
presentation flags human hepatocytes for destruction after 
transduction by adeno-associated viral vectors. J Clin Invest 2009; 
119: 1688-95. 
[55]  Nathwani AC, Gray, JT, Ng, CYC, et al. Self complementary 
adeno-associated virus vectors containing a novel liver-specific 
human factor IX expression cassette enable highly efficient 
transduction of murine and nonhuman primate liver Blood 2006; 
107: 2653-2661. 
[56]  Nathwani A, Tuddenham, E, Rosales, C, et al. Early Clinical Trial 
Results Following Administration of a Low Dose of a Novel Self 
Complementary Adeno-Associated Viral Vector Encoding Human 
Factor IX In Two Subjects with Severe Hemophilia B. Blood 2010; 
116: A248. 
[57]  Guilcher GM, Scully, MF, Harvey, M, Hand, JP. Treatment of 
intracranial and extracranial haemorrhages in a neonate with severe 
haemophilia B with recombinant factor IX infusion. Haemophilia 
2005; 11: 411-4. 
[58]  Pollmann H, Richter, H, Ringkamp, H, Jurgens, H. When are 
children diagnosed as having severe haemophilia and when do they 
start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 
1999; 158 Suppl 3: S166-70. 
[59]  Santagostino E, Mancuso, ME. Prevention of arthropathy in 
haemophilia: prophylaxis. Haemophilia 2008; 14 Suppl 6: 16-9. Perinatal Gene Transfer to the Liver  Current Pharmaceutical Design, 2011, Vol. 17, No. 24    2539 
[60]  Mancuso ME, Graca, L, Auerswald, G, Santagostino, E. 
Haemophilia care in children--benefits of early prophylaxis for 
inhibitor prevention. Haemophilia 2009; 15 Suppl 1: 8-14. 
[61]  Xu L, Gao, C, Sands, MS, et al. Neonatal or hepatocyte growth 
factor-potentiated adult gene therapy with a retroviral vector results 
in therapeutic levels of canine factor IX for hemophilia B. Blood 
2003; 101: 3924-3932. 
[62]  Zhang J, Xu, L, Haskins, ME, Ponder, KP. Neonatal gene transfer 
with a retroviral vector results in tolerance to human factor IX in 
mice and dogs. Blood 2004; 103: 143-51. 
[63]  Xu L, Nichols, TC, Sarkar, R, et al. Absence of a desmopressin 
response after therapeutic expression of factor VIII in hemophilia 
A dogs with liver-directed neonatal gene therapy. Proc Natl Acad 
Sci USA 2005. 
[64]  Xu L, Mei, M, Ma, X, Ponder, KP. High expression reduces an 
antibody response after neonatal gene therapy with B domain-
deleted human factor VIII in mice. J Thromb Haemost 2007; 5: 
1805-12. 
[65]  VandenDriessche T, Vanslembrouck, V, Goovaerts, I, et al. Long-
term expression of human coagulation factor VIII and correction of 
hemophilia A after in vivo retroviral gene transfer in factor VIII- 
deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-84. 
[66]  Waddington SN, Nivsarkar, M, Mistry, A, et al. Permanent 
phenotypic correction of Haemophilia B in immunocompetent mice 
by prenatal gene therapy. Blood 2004; 104: 2714-21. 
[67]  Ward NJ, Buckley, SMK, Waddington, SN, et al. Codon 
optimisation of human factor VIII cDNAs leads to high level 
expression. Blood 2010; 117: 798-807. 
[68]  Howe SJ, Mansour, MR, Schwarzwaelder, K, et al. Insertional 
mutagenesis combined with acquired somatic mutations causes 
leukemogenesis following gene therapy of SCID-X1 patients. J 
Clin Invest 2008; 118: 3143-3150. 
[69]  Lipshutz GS, Sarkar, R, Flebbe-Rehwaldt, L, Kazazian, H, 
Gaensler, KM. Short-term correction of factor VIII deficiency in a 
murine model of hemophilia A after delivery of adenovirus murine 
factor VIII in utero. Proc Natl Acad Sci USA 1999; 96: 13324-9. 
[70]  Tuddenham EG, Ingerslev, J, Norengaard Sorensen, L, et al. 
Genetic aspects and research development in haemostasis. 
Haemophilia 2008; 14: 113-118. 
[71]  Hu C, Cela, RG, Suzuki, M, Lee, B, Lipshutz, GS. Neonatal helper-
dependent adenoviral vector gene therapy mediates correction of 
hemophilia A and tolerance to human factor VIII. Proc Natl Acad 
Sci USA 2011; 108: 2082-2087. 
[72]  Schneider H, Mühle, C, Douar, AM, et al. Sustained delivery of 
therapeutic concentrations of human clotting factor IX - a 
comparison of adenoviral and AAV vectors administered in utero. 
J. Gene Med. 2002; 4: 46-53. 
[73]  Sabatino DE, Mackenzie, TC, Peranteau, W, et al. Persistent 
Expression of hF.IX After Tolerance Induction by In Utero or 
Neonatal Administration of AAV-1-F.IX in Hemophilia B Mice. 
Mol Ther 2007; 12: 12. 
[74]  David AL, McIntosh, J, Peebles, DM, et al. Recombinant adeno-
associated virus-mediated in utero gene transfer gives therapeutic 
transgene expression in the sheep. Hum Gene Ther 2010; 22: 419-
426. 
[75]  Mattar CNZ, Nathwani, AC, Waddington, SN, et al. Stable human 
FIX expression after Intrauterine Gene Transfer of Self-
complementary Adeno-Associated Viral Vector 5 and 8 in 
Macaques. Mol Ther 2011; In Press. 
[76]  Menegatti M, Peyvandi, F. Factor X deficiency. Semin Thromb 
Hemost 2009; 35: 407-15. 
[77]  Herrmann FH, Navarette, M, Salazar-Sanchez, L, et al. 
Homozygous Factor X gene mutations Gly380Arg and 
Tyr163delAT are associated with perinatal intracranial 
hemorrhage. J Pediatr 2005; 146: 128-30. 
[78]  Le M, Okuyama, T, Cai, SR, et al. Therapeutic levels of functional 
human factor X in rats after retroviral-mediated hepatic gene 
therapy. Blood 1997; 89: 1254-9. 
[79]  Xu L, Daly, T, Gao, C, et al. CMV-beta-Actin Promoter Directs 
Higher Expression from an Adeno- Associated Viral Vector in the 
Liver than the Cytomegalovirus or Elongation Factor 1alpha 
Promoter and Results in Therapeutic Levels of Human Factor X in 
Mice. Hum Gene Ther 2001; 12: 563-73. 
[80]  McVey JH, Boswell, E, Mumford, AD, Kemball-Cook, G, 
Tuddenham, EG. Factor VII deficiency and the FVII mutation 
database. Hum Mutat 2001; 17: 3-17. 
[81]  Peyvandi F, Kaufman, RJ, Seligsohn, U, et al. Rare bleeding 
disorders. Haemophilia 2006; 12 Suppl 3: 137-42. 
[82]  Binny CJ, McIntosh, JH, Tuddenham, E, et al. Assessing the 
Potential of Perinatal Gene Transfer Using Congenital Factor VII 
Deficiency as a Model System. Blood 2010; 116: A247. 
[83]  Loirat C, Veyradier, A, Girma, JP, Ribba, AS, Meyer, D. 
Thrombotic thrombocytopenic purpura associated with von 
Willebrand factor-cleaving protease (ADAMTS13) deficiency in 
children. Semin Thromb Hemost 2006; 32: 90-7. 
[84]  Niiya M, Endo, M, Shang, D, et al. Correction of ADAMTS13 
Deficiency by In Utero Gene Transfer of Lentiviral Vector 
encoding ADAMTS13 Genes. Mol Ther 2008; 17: 34-41. 
[85]  Summar ML. In Pagon RA, Bird TD, Dolan CR, Stephens K, 
editors. GeneReviews [Internet]. Seattle (WA): University of 
Washington, Seattle; 1993- 1993. 
[86]  McBride KL, Miller, G, Carter, S, et al. Developmental outcomes 
with early orthotopic liver transplantation for infants with neonatal-
onset urea cycle defects and a female patient with late-onset 
ornithine transcarbamylase deficiency. Pediatrics 2004; 114: e523-
6. 
[87]  Ensenauer R, Tuchman, M, El-Youssef, M, et al. Management and 
outcome of neonatal-onset ornithine transcarbamylase deficiency 
following liver transplantation at 60 days of life. Mol Genet Metab 
2005; 84: 363-6. 
[88]  Filloux F, Townsend, JJ, Leonard, C. Ornithine transcarbamylase 
deficiency: neuropathologic changes acquired in utero. J Pediatr 
1986; 108: 942-5. 
[89]  Stratford-Perricaudet LD, Levrero, M, Chasse, JF, Perricaudet, M, 
Briand, P. Evaluation of the transfer and expression in mice of an 
enzyme-encoding gene using a human adenovirus vector. Hum 
Gene Ther 1990; 1: 241-56. 
[90]  Morsy MA, Zhao, JZ, Ngo, TT, et al. Patient selection may affect 
gene therapy success. Dominant negative effects observed for 
ornithine transcarbamylase in mouse and human hepatocytes. J 
Clin Invest 1996; 97: 826-32. 
[91]  Mian A, McCormack, WM, Jr., Mane, V, et al. Long-Term 
Correction of Ornithine Transcarbamylase Deficiency by WPRE-
Mediated Overexpression Using a Helper-Dependent Adenovirus. 
Mol Ther 2004; 10: 492-9. 
[92]  Brunetti-Pierri N, Clarke, C, Mane, V, et al. Phenotypic correction 
of ornithine transcarbamylase deficiency using low dose helper-
dependent adenoviral vectors. J Gene Med 2008; 10: 890-6. 
[93]  Moscioni D, Morizono, H, McCarter, RJ, et al. Long-term 
correction of ammonia metabolism and prolonged survival in 
ornithine transcarbamylase-deficient mice following liver-directed 
treatment with adeno-associated viral vectors. Mol Ther 2006; 14: 
25-33. 
[94]  Cunningham SC, Spinoulas, A, Carpenter, KH, et al. AAV2/8-
mediated correction of OTC deficiency is robust in adult but not 
neonatal Spf(ash) mice. Mol Ther 2009; 17: 1340-6. 
[95]  Gau CL, Rosenblatt, RA, Cerullo, V, et al. Short-term Correction 
of Arginase Deficiency in a Neonatal Murine Model With a 
Helper-dependent Adenoviral Vector. Mol Ther 2009; 17: 1155-
1163. 
[96]  Ye X, Whiteman, B, Jerebtsova, M, Batshaw, ML. Correction of 
argininosuccinate synthetase (AS) deficiency in a murine model of 
citrullinemia with recombinant adenovirus carrying human AS 
cDNA. Gene Ther 2000; 7: 1777-82. 
[97]  Ogier de Baulny H, Saudubray, JM. Branched-chain organic 
acidurias. Semin Neonatol 2002; 7: 65-74. 
[98]  Saudubray JM, Nassogne, MC, de Lonlay, P, Touati, G. Clinical 
approach to inherited metabolic disorders in neonates: an overview. 
Semin Neonatol 2002; 7: 3-15. 
[99]  Seashore MR. In Pagon RA, Bird TD, Dolan CR, Stephens K, 
editors. GeneReviews [Internet]. Seattle (WA): University of 
Washington, Seattle; 1993- 1993. 
[100]  Homanics GE, Skvorak, K, Ferguson, C, Watkins, S, Paul, HS. 
Production and characterization of murine models of classic and 
intermediate maple syrup urine disease. BMC Med Genet 2006; 7: 
33. 
[101]  Chandler RJ, Chandrasekaran, S, Carrillo-Carrasco, N, et al. 
Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a 
Neonatal Lethal Murine Model of Propionic Acidemia. Hum Gene 
Ther 2011; 22: 477-481. 2540    Current Pharmaceutical Design, 2011, Vol. 17, No. 24  McKay et al. 
[102]  Chandler RJ, Venditti, CP. Adenovirus-Mediated Gene Delivery 
Rescues a Neonatal Lethal Murine Model of mut(0) Methylmalonic 
Acidemia. Hum Gene Ther 2008; 19: 53-60. 
[103]  Carrillo-Carrasco N, Chandler, RJ, Chandrasekaran, S, Venditti, 
CP. Liver-directed recombinant adeno-associated viral gene 
delivery rescues a lethal mouse model of methylmalonic acidemia 
and provides long-term phenotypic correction. Hum Gene Ther 
2010; 21: 1147-54. 
[104]  Hofherr S, Senac, JS, Chen, CY, et al. Short-term Rescue of 
Neonatal Lethality in a Mouse Model of Propionic Acidemia by 
Gene Therapy. Hum Gene Ther 2009; 20: 169-180. 
[105]  Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7: 75-83. 
[106]  Clarke LA. The mucopolysaccharidoses: a success of molecular 
medicine. Expert Rev Mol Med 2008; 10: e1. 
[107]  Peters C, Shapiro, EG, Anderson, J, et al. Hurler syndrome: II. 
Outcome of HLA-genotypically identical sibling and HLA-
haploidentical related donor bone marrow transplantation in fifty-
four children. The Storage Disease Collaborative Study Group. 
Blood 1998; 91: 2601-8. 
[108]  Ponder KP, Haskins, ME. Gene therapy for 
mucopolysaccharidosis. Expert Opin Biol Ther 2007; 7: 1333-45. 
[109]  Kamata Y, Tanabe, A, Kanaji, A, et al. Long-term normalization in 
the central nervous system, ocular manifestations, and skeletal 
deformities by a single systemic adenovirus injection into neonatal 
mice with mucopolysaccharidosis VII. Gene Ther 2003; 10: 406-
14. 
[110]  Kanaji A, Kosuga, M, Li, XK, et al. Improvement of skeletal 
lesions in mice with mucopolysaccharidosis type vii by neonatal 
adenoviral gene transfer. Mol Ther 2003; 8: 718-25. 
[111]  Hartung SD, Frandsen, JL, Pan, D, et al. Correction of metabolic, 
craniofacial, and neurologic abnormalities in MPS I mice treated at 
birth with adeno-associated virus vector transducing the human 
alpha-L-iduronidase gene. Mol Ther 2004; 9: 866-75. 
[112]  Donsante A, Levy, B, Vogler, C, Sands, MS. Clinical response to 
persistent, low-level beta-glucuronidase expression in the murine 
model of mucopolysaccharidosis type VII. J Inherit Metab Dis 
2007; 30: 227-38. 
[113]  Cardone M, Polito, VA, Pepe, S, et al. Correction of Hunter 
syndrome in the MPSII mouse model by AAV2/8-mediated gene 
delivery. Hum Mol Genet 2006; 15: 1225-36. 
[114]  Tessitore A, Faella, A, O'Malley, T, et al. Biochemical, 
pathological, and skeletal improvement of mucopolysaccharidosis 
VI after gene transfer to liver but not to muscle. Mol Ther 2008; 
16: 30-7. 
[115]  Chung S, Ma, X, Liu, Y, et al. Effect of neonatal administration of 
a retroviral vector expressing alpha-l-iduronidase upon lysosomal 
storage in brain and other organs in mucopolysaccharidosis I mice. 
Mol Genet Metab 2007; 90: 181-192. 
[116]  Liu Y, Xu, L, Hennig, AK, et al. Liver-directed neonatal gene 
therapy prevents cardiac, bone, ear, and eye disease in 
mucopolysaccharidosis I mice. Mol Ther 2005; 11: 35-47. 
[117]  Ponder KP, Wang, B, Wang, P, et al. Mucopolysaccharidosis I cats 
mount a cytotoxic T lymphocyte response after neonatal gene 
therapy that can be blocked with CTLA4-Ig. Mol Ther 2006; 14: 5-
13. 
[118]  Meertens L, Zhao, Y, Rosic-Kablar, S, et al. In utero injection of 
alpha-L-iduronidase-carrying retrovirus in canine 
mucopolysaccharidosis type I: infection of multiple tissues and 
neonatal gene expression. Hum Gene Ther 2002; 13: 1809-20. 
[119]  Traas AM, Wang, P, Ma, X, et al. Correction of clinical 
manifestations of canine mucopolysaccharidosis I with neonatal 
retroviral vector gene therapy. Mol Ther 2007; 15: 1423-31. 
[120]  Xu L, Mango, RL, Sands, MS, et al. Evaluation of Pathological 
Manifestations of Disease in Mucopolysaccharidosis VII Mice after 
Neonatal Hepatic Gene Therapy. Mol Ther 2002; 6: 745-58. 
[121]  Ponder KP, Melniczek, JR, Xu, L, et al. Therapeutic neonatal 
hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl 
Acad Sci USA 2002; 99: 13102-7. 
[122]  Sleeper MM, Fornasari, B, Ellinwood, NM, et al. Gene therapy 
ameliorates cardiovascular disease in dogs with 
mucopolysaccharidosis VII. Circulation 2004; 110: 815-20. 
[123]  Mango RL, Xu, L, Sands, MS, et al. Neonatal retroviral vector-
mediated hepatic gene therapy reduces bone, joint, and cartilage 
disease in mucopolysaccharidosis VII mice and dogs. Mol Genet 
Metab 2004; 82: 4-19. 
[124]  Wang B, O'Malley T, M, Xu, L, et al. Expression in blood cells 
may contribute to biochemical and pathological improvements after 
neonatal intravenous gene therapy for mucopolysaccharidosis VII 
in dogs. Mol Genet Metab 2005. 
[125]  Casal ML, Wolfe, JH. In utero transplantation of fetal liver cells in 
the mucopolysaccharidosis type VII mouse results in low-level 
chimerism, but overexpression of beta-glucuronidase can delay 
onset of clinical signs. Blood 2001; 97: 1625-1634. 
[126]  Metcalf JA, Ma, X, Linders, B, et al. A Self-inactivating gamma-
Retroviral Vector Reduces Manifestations of 
Mucopolysaccharidosis I in Mice. Mol Ther 2009; 18: 334-342. 
[127]  Ogawa K, Hirai, Y, Ishizaki, M, et al. Long-term inhibition of 
glycosphingolipid accumulation in Fabry model mice by a single 
systemic injection of AAV1 vector in the neonatal period. Mol 
Genet Metab 2009; 96: 91-6. 
[128]  Wolfsdorf JI, Weinstein, DA. Glycogen storage diseases. Rev 
Endocr Metab Disord 2003; 4: 95-102. 
[129]  Ozen H. Glycogen storage diseases: new perspectives. World J 
Gastroenterol 2007; 13: 2541-53. 
[130]  Koeberl DD, Kishnani, PS, Chen, YT. Glycogen storage disease 
types I and II: treatment updates. J Inherit Metab Dis 2007; 30: 
159-64. 
[131]  Zingone A, Hiraiwa, H, Pan, CJ, et al. Correction of glycogen 
storage disease type 1a in a mouse model by gene therapy. J Biol 
Chem 2000; 275: 828-32. 
[132]  Somia N, Verma, IM. Gene therapy: trials and tribulations. Nat Rev 
Genet 2000; 1: 91-9. 
[133]  Ghosh A, Allamarvdasht, M, Pan, CJ, et al. Long-term correction 
of murine glycogen storage disease type Ia by recombinant adeno-
associated virus-1-mediated gene transfer. Gene Ther 2006; 13: 
321-9. 
[134]  Koeberl DD, Sun, BD, Damodaran, TV, et al. Early, sustained 
efficacy of adeno-associated virus vector-mediated gene therapy in 
glycogen storage disease type Ia. Gene Ther 2006; 13: 1430. 
[135]  Koeberl DD, Pinto, C, Sun, B, et al. AAV vector-mediated reversal 
of hypoglycemia in canine and murine glycogen storage disease 
type Ia. Mol Ther 2008; 16: 665-72. 
[136]  Weinstein DA, Correia, CE, Conlon, T, et al. AAV-Mediated 
Correction of a Canine Model of Glycogen Storage Disease Type 
Ia. Hum Gene Ther 2010. 
[137]  Koeberl DD, Sun, B, Bird, A, et al. Efficacy of helper-dependent 
adenovirus vector-mediated gene therapy in murine glycogen 
storage disease type Ia. Mol Ther 2007; 15: 1253-8. 
[138]  Di Mauro S. Muscle glycogenoses: an overview. Acta Myol 2007; 
26: 35-41. 
[139]  Watchko JF, Lin, Z. Exploring the genetic architecture of neonatal 
hyperbilirubinemia. Semin Fetal Neonatal Med 2010; 15: 169-75. 
[140] Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-
Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor 
syndrome). Best Pract Res Clin Gastroenterol 2010; 24: 555-71. 
[141]  Schauer R, Stangl, M, Lang, T, et al. Treatment of Crigler-Najjar 
type 1 disease: relevance of early liver transplantation. J Pediatr 
Surg 2003; 38: 1227-31. 
[142]  Seppen J, van der Rijt, R, Looije, N, et al. Long-term correction of 
bilirubin UDPglucuronyltransferase deficiency in rats by in utero 
lentiviral gene transfer. Mol Ther 2003; 8: 593-9. 
[143]  Seppen J, van Til, NP, van der Rijt, R, et al. Immune response to 
lentiviral bilirubin UDP-glucuronosyltransferase gene transfer in 
fetal and neonatal rats. Gene Ther 2006; 13: 672-677. 
[144]  Matsui H, Hegadorn, C, Ozelo, M, et al. A MicroRNA-regulated 
and GP64-pseudotyped Lentiviral Vector Mediates Stable 
Expression of FVIII in a Murine Model of Hemophilia A. Mol Ther 
2011; 19: 723-730. 
[145]  Nguyen TH, Aubert, D, Bellodi-Privato, M, et al. Critical 
assessment of lifelong phenotype correction in hyperbilirubinemic 
Gunn rats after retroviral mediated gene transfer. Gene Ther 2007; 
14: 1270-7. 
[146]  Carbonaro DA, Jin, X, Petersen, D, et al. In vivo transduction by 
intravenous injection of a lentiviral vector expressing human ADA 
into neonatal ADA gene knockout mice: a novel form of enzyme 
replacement therapy for ADA deficiency. Mol Ther 2006; 13: 
1110-20. 
[147]  Spitzer D, Wu, X, Ma, X, et al. Cutting edge: treatment of 
complement regulatory protein deficiency by retroviral in vivo gene 
therapy. J Immunol 2006; 177: 4953-6. Perinatal Gene Transfer to the Liver  Current Pharmaceutical Design, 2011, Vol. 17, No. 24    2541 
[148]  Talbot GE, Waddington, SN, Bales, O, Tchen, RC, Antoniou, MN. 
Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene 
Transfer. Mol Ther 2010; 18: 601-608. 
[149]  Tittiger M, Ma, X, Xu, L, Ponder, KP. Neonatal intravenous 
injection of a gammaretroviral vector has a low incidence of tumor 
induction in mice. Hum Gene Ther 2008; 19: 1317-23. 
[150]  Donsante A, Vogler, C, Muzyczka, N, et al. Observed incidence of 
tumorigenesis in long-term rodent studies of rAAV vectors. Gene 
Ther 2001; 8: 1343-6. 
[151]  Donsante A, Miller, DG, Li, Y, et al. AAV vector integration sites 
in mouse hepatocellular carcinoma. Science 2007; 317: 477. 
[152]  Nathwani AC, Rosales, C, McIntosh, J, et al. Long-term safety and 
efficacy following systemic administration of a self-complementary 
AAV vector encoding human FIX pseudotyped with serotype 5 and 
8 capsid proteins. Mol Ther 2011; 19: 876-885. 
[153]  Flageul M, Aubert, D, Pichard, V, et al. Transient expression of 
genes delivered to newborn rat liver using recombinant adeno-
associated virus 2/8 vectors. J Gene Med 2009; 11: 689-96. 
[154]  Inagaki K, Piao, C, Kotchey, NM, Wu, X, Nakai, H. Frequency and 
spectrum of genomic integration of recombinant adeno-associated 
virus serotype 8 vector in neonatal mouse liver. J Virol 2008; 82: 
9513-24. 
[155]  Ponder KP. Immunology of neonatal gene transfer. Curr Gene Ther 
2007; 7: 403-10. 
[156]  Billingham RE, Brent, L, Medawar, PB. Actively acquired 
tolerance of foreign cells. Nature 1953; 172: 603-606. 
[157]  Jiang H, van de Ven, C, Baxi, L, Satwani, P, Cairo, MS. 
Differential gene expression signatures of adult peripheral blood vs 
cord blood monocyte-derived immature and mature dendritic cells. 
Exp Hematol 2009; 37: 1201-15. 
[158]  Goldenberg NA, Manco-Johnson, MJ. Protein C deficiency. 
Haemophilia 2008; 14: 1214-21. 
[159]  Pollock-Barziv SM, McCrindle, BW, West, LJ, Dipchand, AI. 
Waiting before birth: outcomes after fetal listing for heart 
transplantation. Am J Transplant 2008; 8: 412-8. 
[160]  Guo Y, Zhang, X, Huang, J, et al. Relationships between 
hematopoiesis and hepatogenesis in the midtrimester fetal liver 
characterized by dynamic transcriptomic and proteomic profiles. 
PLoS ONE 2009; 4: e7641. 
[161]  Collardeau-Frachon S, Scoazec, JY. Vascular development and 
differentiation during human liver organogenesis. Anat Rec 
(Hoboken) 2008; 291: 614-27. 
[162]  Hayes IM, Collins, V, Sahhar, M, Wraith, JE, Delatycki, MB. 
Newborn screening for mucopolysaccharidoses: opinions of 
patients and their families. Clin Genet 2007; 71: 446-50. 
[163]  Bainbridge JW, Smith, AJ, Barker, SS, et al. Effect of Gene 
Therapy on Visual Function in Leber's Congenital Amaurosis. N 
Engl J Med 2008; 358: 2231-2239. 
[164]  Maguire AM, Simonelli, F, Pierce, EA, et al. Safety and Efficacy 
of Gene Transfer for Leber's Congenital Amaurosis. N Engl J Med 
2008; 358: 2240-2248. 
[165]  Cideciyan AV, Hauswirth, WW, Aleman, TS, et al. Human RPE65 
gene therapy for Leber congenital amaurosis: persistence of early 
visual improvements and safety at 1 year. Hum Gene Ther 2009; 
20: 999-1004. 
[166]  Hacein-Bey-Abina S, Le Deist, F, Carlier, F, et al. Sustained 
correction of X-linked severe combined immunodeficiency by ex 
vivo gene therapy. N Engl J Med 2002; 346: 1185-93. 
[167]  Aiuti A, Slavin, S, Aker, M, et al. Correction of ADA-SCID by 
stem cell gene therapy combined with nonmyeloablative 
conditioning. Science 2002; 296: 2410-3. 
[168]  Cartier N, Hacein-Bey-Abina, S, Bartholomae, CC, et al. 
Hematopoietic stem cell gene therapy with a lentiviral vector in X-
linked adrenoleukodystrophy. Science 2009; 326: 818-23. 
[169]  Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29: 
121-8. 
[170]  Cao H, Yang, T, Li, XF, et al. Readministration of helper-
dependent adenoviral vectors to mouse airway mediated via 
transient immunosuppression. Gene Ther 2011; 18: 173-81. 
[171]  Phillips JB, Billson, VR, Forbes, AB. Autopsy standards for fetal 
lengths and organ weights of an Australian perinatal population. 
Pathology 2009; 41: 515-26. 
[172]  Bolton-Maggs PH, Pasi, KJ. Haemophilias A and B. Lancet 2003; 
361: 1801-9. 
[173]  Hesiod. Theogony and Works and Days, Oxford Paperbacks 2008. 
 
  
Received: June 16, 2011              Accepted: June 28, 2011 
 